Coronavirus [NEW TOPIC PAGE]

Hot Topics of the Day|PHGKB

 Coronavirus

Precision Public Health as a Key Tool in the COVID-19 Response
SA Rasmussen et al, JAMA, August 12, 2020

The COVID-19 pandemic provides an opportunity for further evolution of the field of precision public health, as new tools and technologies begin to complement traditional medical and public health approaches to prevention and control. Despite challenges, at no time has precision public health been needed more than now.

Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans
PS Arunachalam et al, Science, August 11, 2020

The PHA4GE SARS-CoV-2 Contextual Data Specification for Open Genomic Epidemiology
EJ Griffith et al, preprints.org, August 2020

A negative COVID-19 test does not mean recovery
NA Alwan, Nature, August 11, 2020

Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults
MJ Mulligan et al, Nature, August 12, 2020

We report the available safety, tolerability, and immunogenicity data from an ongoing placebo-controlled, observer-blinded dose escalation study among 45 healthy adults, 18 to 55 years of age, randomized to receive 2 doses, separated by 21 days, of 10 µg, 30 µg, or 100 µg of BNT162b1, a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine.

Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis
L Walz et al, MEDRXIV, August 11, 2020

Mass molecular testing for COVID19 using NGS-based technology and a highly scalable workflow
F de Mello Malta et al, MEDRXIV, August 11, 2020

The effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review
D Jarrom et al, MEDRXIV, August 11, 2020

Evidence is rapidly emerging on the effectiveness of tests for COVID-19 diagnosis and management, but important uncertainties about their effectiveness and most appropriate application remain. Estimates of diagnostic accuracy should be interpreted bearing in mind the absence of a definitive reference standard to diagnose or rule out COVID-19 infection.

Racial Disproportionality in Covid Clinical Trials
DB Chastain et al, NEJM, August 10, 2020

Lack of diversity in clinical trials may stem from long-standing medical distrust on the part of minority communities, but the problem may be compounded by cost (e.g., hidden costs for such requirements as fuel, parking, meals, and lodging), poor health literacy, lack of information, language barriers, limited accessibility, and implicit biases against minorities.